Kouji Kobiyama

Kouji Kobiyama

Auto-generated profile, based on publicly available information

Kouji Kobiyama

Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2018 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
YKYuki Katayama
Yuki Katayama
MTMasashi Tachibana
Masashi Tachibana
NKNozomi Kurisu
Nozomi Kurisu
YOYukako Oya
Yukako Oya
YTYuichi Terasawa
Yuichi Terasawa
FSFuminori Sakurai
Fuminori Sakurai
Oncolytic reovirus, which possesses 10 segments of dsRNA genome, mediates antitumor effects via not only virus replication in a tumor cell–specific manner, but also activation of antitumor immunity; however, the mechanism(s) of reovirus-induced activation of antitumor immunity have not been fully elucidated. Recent studies have demonstrated that overcoming an immunosuppressive environment in tumor-bearing hosts is important to achieve efficient activation of antitumor immunity. Among the various types of cells involved in immunosuppression, it has been revealed that myeloid-derived suppressor cells (MDSCs) are significantly increased in tumor-bearing hosts and play crucial roles in the immunosuppression in tumor-bearing hosts. In this study, we examined whether reovirus inhibits the immunosuppressive activity of MDSCs, resulting in efficient activation of immune cells after in vivo administration. The results showed that splenic MDSCs recovered from PBS-treated tumor-bearing mice significantly suppressed the Ag-specific proliferation of CD8+ T cells. In contrast, the suppressive activity of MDSCs on T cell proliferation was significantly reduced after reovirus administration. Reovirus also inhibited the immunosuppressive activity of MDSCs in IFN-β promoter stimulator-1 knockout (KO) mice and in wild-type mice. In contrast, the immunosuppressive activity of MDSCs in TLR-3 KO mice was not significantly altered by reovirus treatment. The activation levels of CD4+ and CD8+ T cells were significantly lower in TLR3 KO mice than in wild-type mice after reovirus administration. These results indicate that reovirus inhibits the immunosuppressive activity of MDSCs in a TLR3, but not IFN-β promoter stimulator-1, signaling-dependent manner.

12 August 2018 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
KKKouji Kobiyama
Kouji Kobiyama
MVMelanie Vassallo
Melanie Vassallo
JMJessica Mitzi
Jessica Mitzi
HWHolger Winkels
Holger Winkels
HPHong Pei
Hong Pei
Klaus LeyKlaus Ley
Klaus Ley

15 December 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MLMichelle S.J. Lee
Michelle S.J. Lee
TITakeshi Inoue
Takeshi Inoue
WIWataru Ise
Wataru Ise
JMJulia Matsuo-Dapaah
Julia Matsuo-Dapaah
JWJames B. Wing
James B. Wing
CCCevayir Coban
Cevayir Coban
The germinal center (GC) is a site where somatic hypermutation and clonal selection are coupled for antibody affinity maturation against infections. However, how GCs are formed and regulated is incompletely understood. Here, we identified an unexpected role of Tank-binding kinase-1 (TBK1) as a crucial B cell–intrinsic factor for GC formation. Using immunization and malaria infection models, we show that TBK1-deficient B cells failed to form GC despite normal Tfh cell differentiation, although some malaria-infected B cell–specific TBK1-deficient mice could survive by GC-independent mechanisms. Mechanistically, TBK1 phosphorylation elevates in B cells during GC differentiation and regulates the balance of IRF4/BCL6 expression by limiting CD40 and BCR activation through noncanonical NF-κB and AKTT308 signaling. In the absence of TBK1, CD40 and BCR signaling synergistically enhanced IRF4 expression in Pre-GC, leading to BCL6 suppression, and therefore failed to form GCs. As a result, memory B cells generated from TBK1-deficient B cells fail to confer sterile immunity upon reinfection, suggesting that TBK1 determines B cell fate to promote long-lasting humoral immunity.

6 October 2025 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
YMYasuaki Mohri
Yasuaki Mohri
JNJialiang Nie
Jialiang Nie
HMHironobu Morinaga
Hironobu Morinaga
TKTomoki Kato
Tomoki Kato
TATakahiro Aoto
Takahiro Aoto
ENEmi K. Nishimura
Emi K. Nishimura

18 July 2025 in Science Immunology
Verified
Journal Article
Closed access
BLBo Li
Bo Li
TSTaiki Sakaguchi
Taiki Sakaguchi
HTHaruka Tani
Haruka Tani
TITakayoshi Ito
Takayoshi Ito
MMMari Murakami
Mari Murakami
HKHisako Kayama
Hisako Kayama
Ulcerative colitis (UC) develops through a complicated interaction between the host and microbiota. Intestinal fibroblasts are believed to play crucial roles in the pathogenesis of UC, but the influence of the host-microbiota interaction on the pathophysiology of intestinal fibroblasts remains poorly understood. Here, we demonstrate that OTU deubiquitinase 3 (OTUD3) suppresses pathologic activation of fibroblasts exposed to microbial cyclic GMP-AMP (3′3’-cGAMP) in the colon by deubiquitinating stimulator of interferon genes (STING). Mice harboring a UC risk missense variant in the Otud3 gene showed pathological features of UC in the colon after transplantation of a fecal microbiota with the potential to produce excessive cGAMP from patients with UC. Collectively, these results highlight a mechanism of the interaction between OTUD3 in host fibroblasts and STING-activating microbiota in UC development.

15 April 2025 in EBioMedicine
Verified
Journal Article
Open access
KKKouji Kobiyama
Kouji Kobiyama
DUDaichi Utsumi
Daichi Utsumi
YKYu Kaku
Yu Kaku
ESEita Sasaki
Eita Sasaki
FYFumihiko Yasui
Fumihiko Yasui
KIKen Ishii
Ken Ishii
The global mpox outbreak (2022-2024) highlights the need for effective and safe vaccines, particularly for vulnerable populations. The LC16m8 vaccine, an attenuated vaccinia virus strain for smallpox, shows promise in inducing immunity against the monkeypox virus (MPXV). We conducted a comprehensive immunological evaluation of LC16m8 in mice, non-human primates, and humans. LC16m8 induced strong humoural responses in BALB/c, C57BL/6J, and CAST/EiJ mice, targeting MPXV H3, A35, and M1R antigens, promoting germinal centre B cells and follicular helper T cells, essential for long-term immunity. Vaccinated CAST/EiJ mice showed reduced lung MPXV viral loads, demonstrating efficacy. In humans, LC16m8 enhanced neutralising antibodies against multiple MPXV clades, suggesting broad protection. In cynomolgus monkeys, systemic administration caused localised pox lesions without significantly affecting weight, temperature, or haematological parameters. This cross-species immunological analysis provides preclinical and early clinical insights into LC16m8's efficacy and safety against mpox. While LC16m8 enhanced antibody responses against MPXV clade Ia and Ib, further studies are required to evaluate its efficacy, particularly in naive and immunocompromised populations. This research was supported by AMED under Grant Numbers JP243fa727002, JP243fa727001s0703, and JP243fa627001h0003 (K.J.I), JP24jf0126002, JP24fk0108690, JP243fa627001h0003, and JP243fa727002 (K.S), JP243fa727002 (Y.T.), JP243fa727002 and JP243fa627007h0003 (Y.Y.), and by the Research Support Project for Life Science and Drug Discovery (BINDS) from AMED under Grant Number JP23ama121011 (J.T.), and JP23ama121010 (T.S.), and by the Ministry of Education, Culture, Sports, Science and Technology in Japan under Grant Number 23K06577 (E.S.). AMED under Grant Number JP233fa827017 and JP243fa827017 (F.Y.), JP22fk0108501 (M.K.).